LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 26, 2009--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that it will
release its fourth-quarter and year-end 2008 financial results before
the market opens on Thursday, March 12, 2009.
Management will conduct a conference call at 10:00 a.m. (ET) that
morning to review the Company's fourth-quarter and year-end financial
results. The conference call will be webcast live over the Internet and
can be accessed by logging on to the "Investors" section of the Synta
Pharmaceuticals website, www.syntapharma.com,
prior to the event.
The call also can be accessed by dialing (877) 407-8035 or (201)
689-8035 prior to the start of the call. For those unable to join the
live conference call, a replay will be available from 2:00 p.m. (ET) on
March 12 through midnight (ET) on March 19. To access the replay, dial
(877) 660-6853 or (201) 612-7415 and refer to both account number 286
and conference ID 310879. The webcast also will be archived on the
Company's website.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. Synta has a partnership with
GlaxoSmithKline for the joint development and commercialization of its
lead investigational drug candidate, elesclomol, which has completed
enrollment in a global, pivotal Phase 3 clinical trial for the treatment
of metastatic melanoma. For more information, please visit www.syntapharma.com.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall
Biomedical Communications
Doug MacDougall, 781-235-3060